JP2025510783A5 - - Google Patents

Info

Publication number
JP2025510783A5
JP2025510783A5 JP2024556445A JP2024556445A JP2025510783A5 JP 2025510783 A5 JP2025510783 A5 JP 2025510783A5 JP 2024556445 A JP2024556445 A JP 2024556445A JP 2024556445 A JP2024556445 A JP 2024556445A JP 2025510783 A5 JP2025510783 A5 JP 2025510783A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
domain contains
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510783A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/064940 external-priority patent/WO2023183926A1/en
Publication of JP2025510783A publication Critical patent/JP2025510783A/ja
Publication of JP2025510783A5 publication Critical patent/JP2025510783A5/ja
Pending legal-status Critical Current

Links

JP2024556445A 2022-03-25 2023-03-24 抗ｃｄ９４抗体及びその使用方法 Pending JP2025510783A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263323959P 2022-03-25 2022-03-25
US63/323,959 2022-03-25
PCT/US2023/064940 WO2023183926A1 (en) 2022-03-25 2023-03-24 Anti-cd94 antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2025510783A JP2025510783A (ja) 2025-04-15
JP2025510783A5 true JP2025510783A5 (cg-RX-API-DMAC10.html) 2026-03-23

Family

ID=88102086

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556445A Pending JP2025510783A (ja) 2022-03-25 2023-03-24 抗ｃｄ９４抗体及びその使用方法

Country Status (5)

Country Link
US (1) US20250197505A1 (cg-RX-API-DMAC10.html)
EP (1) EP4499699A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025510783A (cg-RX-API-DMAC10.html)
CN (1) CN119173536A (cg-RX-API-DMAC10.html)
WO (1) WO2023183926A1 (cg-RX-API-DMAC10.html)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030095965A1 (en) * 2001-05-02 2003-05-22 Katrien Van Beneden Antibodies to Ly49E and CD94/NKG2 receptors
AU2015201622A1 (en) * 2005-10-14 2015-04-16 Innate Pharma Compositions and methods for treating proliferative disorders
WO2020205440A1 (en) * 2019-03-29 2020-10-08 Dren Bio, Inc. Methods of reducing large granular lymphocyte and natural killer cell levels
EP4221752A4 (en) * 2020-09-30 2024-12-04 Dren Bio, Inc. ANTI-CD94 ANTIBODIES AND METHODS OF USE THEREOF

Similar Documents

Publication Publication Date Title
US12024566B2 (en) Anti-SIRPalpha antibody
TWI771361B (zh) 人程序性死亡受體pd-1的單株抗體及其片段
JP7366543B2 (ja) Ｂｃｍａ結合分子及びその使用方法
US20240287187A1 (en) Bispecific antibody
JP2020513786A5 (cg-RX-API-DMAC10.html)
JP2020532965A5 (cg-RX-API-DMAC10.html)
CN113454119B (zh) 抗btla抗体
JP2010504755A5 (cg-RX-API-DMAC10.html)
JP2016513467A5 (cg-RX-API-DMAC10.html)
JP2021525544A5 (cg-RX-API-DMAC10.html)
JP2019509014A5 (cg-RX-API-DMAC10.html)
JP7843824B2 (ja) 抗体および使用方法
JP2024541680A5 (cg-RX-API-DMAC10.html)
JP2022528721A5 (cg-RX-API-DMAC10.html)
WO2023040940A1 (zh) Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症
JP2022521956A5 (cg-RX-API-DMAC10.html)
JP2022527084A5 (cg-RX-API-DMAC10.html)
JP2024527576A5 (cg-RX-API-DMAC10.html)
JP2024535692A5 (cg-RX-API-DMAC10.html)
JP2023543835A5 (cg-RX-API-DMAC10.html)
KR20210149044A (ko) 이중 특이성 항체
CN115667311A (zh) 抗cd40抗体组合治疗癌症
TW202118790A (zh) 雙特異性抗體
AU2023329055A1 (en) Cancer treatment comprising an anti-msln/cd137 antibody and a chemotherapeutic
CN120476151A (zh) 用于治疗和抑制过敏性反应的组合物和方法